Ibrutinib and venetoclax for first-line treatment of CLL

Arnon P. Kater, Mark-David Levin, Carsten U. Niemann

Research output: Contribution to journal › Letter › Academic › peer-review

8 Citations (Scopus)

Original language	English
Pages (from-to)	788-789
Number of pages	2
Journal	New England journal of medicine
Volume	381
Issue number	8
DOIs	https://doi.org/10.1056/NEJMc1908754
Publication status	Published - 22 Aug 2019

Access to Document

@article{41899a3267fc4e81bd58cfc0f043ff0d,

title = "Ibrutinib and venetoclax for first-line treatment of CLL",

author = "Kater, {Arnon P.} and Mark-David Levin and Niemann, {Carsten U.}",

year = "2019",

month = aug,

day = "22",

doi = "https://doi.org/10.1056/NEJMc1908754",

language = "English",

volume = "381",

pages = "788--789",

journal = "New England journal of medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "8",

}

TY - JOUR

T1 - Ibrutinib and venetoclax for first-line treatment of CLL

AU - Kater, Arnon P.

AU - Levin, Mark-David

AU - Niemann, Carsten U.

PY - 2019/8/22

Y1 - 2019/8/22

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85071332832&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/31433936

U2 - https://doi.org/10.1056/NEJMc1908754

DO - https://doi.org/10.1056/NEJMc1908754

M3 - Letter

C2 - 31433936

SN - 0028-4793

VL - 381

SP - 788

EP - 789

JO - New England journal of medicine

JF - New England journal of medicine

IS - 8

ER -